SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-156724
Filing Date
2023-05-30
Accepted
2023-05-30 17:20:01
Documents
14
Period of Report
2023-05-30
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d480208d8k.htm   iXBRL 8-K 33755
2 EX-99.1 d480208dex991.htm EX-99.1 11656
6 GRAPHIC g480208g0531020019065.jpg GRAPHIC 3014
  Complete submission text file 0001193125-23-156724.txt   180147

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ctic-20230530.xsd EX-101.SCH 2866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20230530_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20230530_pre.xml EX-101.PRE 11272
8 EXTRACTED XBRL INSTANCE DOCUMENT d480208d8k_htm.xml XML 3433
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 23977830
SIC: 2834 Pharmaceutical Preparations